特发性矮小患儿生长激素受体基因Ex3多态性与重组人生长激素疗效分析

摘要
图/表
参考文献(8)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (954 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的：观察生长激素受体（GHR）基因Ex3多态性与重组人生长激素（rhGH）治疗青春期前特发性矮小（ISS）疗效间的相关性。方法：青春期前ISS患儿30例，均采用rhGH［0.116±0.02 IU/(kg/d)］治疗；其外周血白细胞中抽提基因组DNA，采用多重PCR扩增GHR基因Ex3区域。对不同基因型患儿治疗后生长速率（GV）、年龄对应身高标准差积分（HtSDSCA）及骨龄对应身高标准差积分（HtSDSBA）、预测终身高进行比较。结果：rhGH治疗半年后d3/d3基因型组GV较fl/fl基因型组明显增加［（6.3±1.6）cm/年 vs （3.4±0.5）cm/年，P<0.05］。结论：ISS患儿GHR Ex3基因型与rhGH促生长疗效存在一定关联，d3/d3等位基因型患儿用rhGH治疗后生长速率明显优于fl/fl等位基因型。［中国当代儿科杂志，2010，12（9）：730-733］

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陆文丽
	王伟
	王德芬
	肖园
	黄晓萍
	董治兰

关键词 ：特发性矮小, 重组人生长激素, 生长激素受体, 儿童

Abstract：OBJECTIVE: To assess the influence of growth hormone receptor (GHR) Ex3 genotype on the short-term response to recombinant human growth hormone (rhGH) therapy in children with idiopathic short stature (ISS). METHODS: Thirty prepubertal children with ISS receiving rhGH treatment ［0.116±0.02 IU/(kg/d)］ were randomly recruited. The GHR Ex3 locus was genotyped using a PCR multiplex assay. The growth data including growth velocity, height SDS for chronological age (HtSDSCA), height SDS for bone age (HtSDSBA) and predict final height were compared in children with different GHR genotypes 6 months after rhGH treatment. RESULTS: After 6 months of rhGH treatment, the children with ISS carrying d3/d3 alleles showed a significantly higher increment in growth velocity than those carrying fl/fl alleles (6.3±1.6 cm/year vs 3.4±0.5 cm/year; P<0.05). CONCLUSIONS: The polymorphism in GHR Ex3 is associated with the responsiveness to rhGH treatment, showing that the growth velocity in ISS children with d3/d3 genotype is significantly higher than those with fl/fl genotype.［Chin J Contemp Pediatr, 2010, 12 (9):730-733］

Key words： Idiopathic short stature Recombinant human growth hormone Growth hormone receptor Child

PACS:

R72

引用本文:

陆文丽,王伟,王德芬等. 特发性矮小患儿生长激素受体基因Ex3多态性与重组人生长激素疗效分析[J]. 中国当代儿科杂志, 2010, 12(09): 730-733.

LU Wen-Li,WANG Wei,WANG De-Fen et al. Relationship between the polymorphism of growth hormone receptor Ex3 and the efficacy of rhGH treatment in children with idiopathic short stature[J]. CJCP, 2010, 12(09): 730-733.

链接本文:

http://www.zgddek.com/CN/ 或 http://www.zgddek.com/CN/Y2010/V12/I09/730

	［1］国家体育总局群体司编. 2000年国民体质监测报告［M］. 北京：体育大学出版社, 2002: 105, 124.
	［2］Pantel J, Grulich-Henn J, Bettendorf M, Strasburger CJ, Heinrich U, Amselem S. Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform［J］. J Clin Endocrinol Metab, 2003, 88(4):1705-1710.
	［3］Hintz RL, Attie KM, Baptista J, Roche A. Effect of growth hormone treatment on adult height of children with idiopathic short stature［J］. N Engl J Med, 1999, 340（7）: 502-507.
	［4］Bryant J, Baxter L, Cave C, Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents［J］. Cochrane Database Syst Rev, 2003: CD004440.
	［5］Thomas FJ, McLeod HL, Watters JW. Pharmacogenomics: the influence of genomic variation on drug response［J］. Curr Top Med Chem, 2004, 4(13):1399-1409.
	［6］Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneresl P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone［J］. Nat Genet, 2004, 36(7):720-724.
	［7］Binder G, Baur F, Schweizer Ranke MB. The d3-Growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestationalage children［J］. J Clin Endocrinol Metab, 2006, 91(2): 659-664.
	［8］Alexander AL, Frederico G, Marchisotti LR, Luciani RC, Berenice BM, Ivo JP. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on firstyear growth response and final height in patients with severe GH deficiency［J］. J Clin Endocrinol Metab, 2006, 91(3):795-796.